Scarica l'app Stockscreener
37.08
3.32%
1.19
Pre-mercato:
37.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.89
Aprire:
$36.02
Volume 24 ore:
603.67K
Relative Volume:
1.38
Capitalizzazione di mercato:
$1.36B
Reddito:
$154.15M
Utile/perdita netta:
$-33.58M
Rapporto P/E:
-38.62
EPS:
-0.96
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+4.10%
1M Prestazione:
+20.94%
6M Prestazione:
+2.71%
1 anno Prestazione:
+48.26%
Intervallo 1D:
$35.80
$38.09
Intervallo di 1 settimana:
$33.33
$38.09
Portata 52W:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
Nome
Harrow Inc
Settore
Telefono
615.733.4731
Indirizzo
1A BURTON HILLS BLVD, NASHVILLE, CA
Confronta HROW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
37.08 | 1.31B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | BTIG Research | Buy |
| 2025-06-10 | Iniziato | William Blair | Outperform |
| 2025-02-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-04 | Reiterato | B. Riley Securities | Buy |
| 2024-04-11 | Iniziato | Craig Hallum | Buy |
| 2022-09-08 | Ripresa | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-09-24 | Iniziato | Aegis Capital | Buy |
| 2021-07-02 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Harrow Inc Borsa (HROW) Ultime notizie
Is Harrow Inc. a good long term investmentAccelerated wealth expansion - Autocar Professional
What drives Harrow Inc. stock priceMarket-beating returns - Autocar Professional
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
What analysts say about Harrow Inc. stockRapid profit acceleration - jammulinksnews.com
Harrow Inc. Stock Analysis and ForecastMassive wealth growth - PrintWeekIndia
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener
Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest
Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha
Ongoing Securities Investigation into Harrow, Inc. (HROW)Contact Levi & Korsinsky - ACCESS Newswire
HROW Investor Notice: Levi & Korsinsky Investigates Harrow, Inc. for Securities Law Violations - ACCESS Newswire
Harrow Inc Azioni (HROW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):